Purdue Pharma’s sentencing highlights both progress in accountability and the urgent need to strengthen how we respond to the opioid crisis.
The sentencing of Purdue Pharma marks a significant moment in the long fight for accountability in the opioid epidemic, but it also underscores the limits of our current system to deliver true justice for the families and communities harmed.
Purdue admitted to defrauding regulators and paying illegal kickbacks to drive the prescribing of highly addictive opioids; actions that helped fuel a crisis that has taken hundreds of thousands of lives. While this ruling and the billions tied to the broader settlement represent an important step, no financial penalty can fully repair the damage done.
What matters now is what happens next.
Opioid settlement funds, many of which are derived from cases like this, represent a once-in-a-generation opportunity to save lives. These dollars must be invested with urgency and accountability in proven, evidence-based solutions: expanding access to high-quality treatment, supporting recovery, preventing overdose, and strengthening data-driven systems that ensure care actually works.
We cannot afford to repeat past mistakes. Too often, funding meant to address substance use has been diverted or spent without clear impact. States must commit to transparency, community engagement, and adherence to evidence-based standards so these resources reach the people who need them most.
This moment should serve as both a reckoning and a turning point. Accountability is not just about penalties—it’s about ensuring that the legacy of this crisis is a stronger, more effective system of care that prevents future harm and supports recovery for every person who needs it.
Learn more about how opioid settlement funds are tracked around the country.
